CRITERIA FOR PRECLINICAL ALZHEIMER’S DISEASE – June 2, 2010 Preclinical Alzheimer’s Disease Workgroup
نویسندگان
چکیده
Reisa Sperling, Brigham and Women’s Hospital (Chair) Laurel Beckett, University of California, Davis David Bennett, Rush University Medical Center Suzanne Craft, VA Puget Sound Health Care System Anne Fagan, Washington University, St Louis Jeffrey Kaye, Oregon Health Science University Tom Montine, University of Washington Denise Park, University of Texas, Dallas Eric Reiman, Banner Alzheimer’s Institute Eric Siemers, Eli Lilly and Company Yaakov Stern, Columbia University Kristine Yaffe, University of California, San Francisco
منابع مشابه
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup
The pathophysiological process of Alzheimer’s disease (AD) is thought to begin many years
متن کاملIntroduction to the recommendations from the National Institute on Aging and the Alzheimer's Association workgroup on diagnostic guidelines for Alzheimer's disease
Background: Criteria for the clinical diagnosis of Alzheimer’s disease (AD) were established in *Corresponding au E-mail address: ja 1552-5260/$ see fro doi:10.1016/j.jalz.201 1984. A broad consensus now exists that these criteria should be revised to incorporate state-ofthe-art scientific knowledge. Methods: The National Institute on Aging (NIA) and the Alzheimer’s Association sponsored a seri...
متن کاملOverestimating the Effects of Healthy Aging
Typical cognitive aging is often defined as aging free of dementia, and yet it does not seem to exclude dementia-related pathology. The most common type of dementia is Alzheimer’s disease (AD) – it is a progressive neurodegenerative disease that affects multiple cognitive domains, including memory, attention, reasoning, judgment, language, as well as behavior. AD accounts for 60–80% of dementia...
متن کاملNeurodegenerative Biomarkers in Healthy Elderly – with special reference to the preclinical pattern of biological and cognitive markers for Alzheimer’s disease
ENGLISH Neurodegenerative Biomarkers in Healthy Elderly – with special reference to the preclinical pattern of biological and cognitive markers for Alzheimer’s disease
متن کاملLong-term forgetting in preclinical Alzheimer's disease
Alzheimer’s disease is characterised by progressive pathophysiological changes that correspond roughly to preclinical (ie, cognitively unimpaired), mild cognitive impairment, and dementia stages. Biomarkers continue to be developed, tested, and used to detect and track the pathophysiological manifestations of this disease. Although neuropsychological tests, clinical ratings, and composite cogni...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2010